Compare AbbVie Inc (ABBV) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while First Trust NASDAQ 100 Technology Index Fund trades at $311.97. The key difference: AbbVie Inc pays a 2.72% dividend while First Trust NASDAQ 100 Technology Index Fund pays none. Which is the better fit depends on your goals.
| ABBV | QTEC | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $335.74 |
52-Week Low | $184.85 | $207.03 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
QTEC trades at $320.77, up 1.84% with neutral technical signals and bullish moving averages. The ETF provides equal-weighted exposure to Nasdaq-100 technology stocks, recently hitting 52-week highs. Support levels cluster around $313-318 while resistance sits at $324-329. Recent news highlights QTEC's role in tech sector exposure amid AI and chip stock momentum.
The ETF's equal-weight approach diversifies tech sector risk, though concentrated tech exposure remains sensitive to sector volatility. Current technical positioning suggests consolidation near pivot points, with institutional interest balanced by valuation concerns in overheated AI segments. Key risks include sector rotation and macroeconomic pressure on growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
